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Abstract
Gastro-esophageal reflux disease (GERD) is partly caused by genetic factors. The underlying susceptibility genes are
currently unknown, with the exception of COL3A1. We used three independent GERD patient cohorts to identify GERD
susceptibility genes. Thirty-six families, demonstrating dominant transmission of GERD were subjected to whole genome
microsatellite genotyping and linkage analysis. Five linked regions were identified. Two families shared a linked region (LOD
3.9 and 2.0) on chromosome 16. We used two additional independent GERD patient cohorts, one consisting of 219 trios
(affected child with parents) and the other an adult GERD case control cohort consisting of 256 cases and 485 controls, to
validate individual genes in the linked region through association analysis. Sixty six single nucleotide polymorphism (SNP)
markers distributed over the nine genes present in the linked region were genotyped in the independent GERD trio cohort.
Transmission disequilibrium test analysis followed by multiple testing adjustments revealed a significant genetic association
for one SNP located in an intron of the gene 4-aminobutyrate aminotransferase (ABAT) (Padj=0.027). This association did
not replicate in the adult case-control cohort, possibly due to the differences in ethnicity between the cohorts. Finally, using
the selective ABAT inhibitor vigabatrin (c-vinyl GABA) in a dog study, we were able to show a reduction of transient lower
esophageal sphincter relaxations (TLESRs) by 57.3611.4 % (p=0.007) and the reflux events from 3.160.4 to 0.860.4
(p=0.007). Our results demonstrate the direct involvement of ABAT in pathways affecting lower esophageal sphincter (LES)
control and identifies ABAT as a genetic risk factor for GERD.
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Introduction
Gastroesophageal reflux disease (GERD) is an increasingly
common gastrointestinal disorder with a prevalence of 25–40% in
the western world [1,2]. GERD symptoms, such as heartburn and
regurgitation, leave affected individuals with a severely impaired
quality of life and place a considerable health economic burden on
society [3,4].
Diagnosis relies on clinical assessment and multidimensional
questionnaires combined with physical examinations such as
endoscopic examination and 24 hour pH measurements of the
esophagus. The disease has been subdivided into erosive reflux
disease (ERD) and non-erosive reflux disease (NERD) [5]. The
patient classification helps predict likelihood of response to proton
pump inhibitors, ERD individuals exhibiting a better response rate
than NERD individuals. ERD is thought to be caused mainly by
acid reflux into the esophagus while NERD may include other
factors such as weakly acidic or non-acidic reflux. Less than half of
affected individuals have the erosive form of the disease where the
esophageal mucosa is damaged by acidic reflux. The majority
suffer from NERD, where affected individuals experience typical
GERD symptoms without visible esophageal injuries [6].
Onset of the disease is variable and occurs among children as
well as in adults. It has been suggested that GERD may originate
in childhood [1,7–10]. In fact, GERD is the most common
esophageal disorder in children and 11% of infants are affected
during their first year of life [11]. However, there are differences
between pediatric and adult GERD such that the erosive form of
the disease is rarely seen in the young [12].
Both environmental and genetic factors contribute to disease
susceptibility. There is a clear genetic component to GERD, as has
been shown in several studies through familial clustering and twin
concordance rates [13–16]. In the large twin study by Cameron
et al. (2002), the genetic heritability was estimated at 31%. However,
with the one exception of COL3A1, the identities of the causative
genes are presently unknown. COL3A1 encodes collagen type III
alpha 1 providing molecular support for the notion that there is a
connective tissue weakness component to GERD [17].
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and alcohol consumption has also been shown to be associated
with an increased risk of acquiring the disease [2]. It is probable
that some of these environmental factors are not present in young
GERD patients, suggesting that the genetic component may be
more penetrant in the young.
Treatment of GERD is primarily provided through proton
pump inhibitors (PPIs) that reduce the acidity of the stomach’s
gastric acid. However, a large proportion of GERD patients do
not benefit from this treatment leaving a large unmet need for new
pharmacological interventions. A large effort has been devoted to
developing drugs that inhibit transient lower esophageal sphincter
relaxations (TLESRs), the major underlying mechanism for
gastroesophageal reflux [18–20], aiming to reduce the number
of reflux events in affected individuals. This research has to some
extent been dependent on animal models, where dogs and ferrets
are the best established models [21,22]. Future anti-reflux drugs
hold the hope of being effective for the treatment of patients who
experience GERD symptoms despite being on PPIs [23].
Genetics can be used to address the underlying disease
mechanisms and provide potential new targets for drug treatment
as well as biomarkers for patient stratification. We have used a
combination of human genetic approaches coupled with validation
in the TLESR dog model to identify 4-aminobutyrate amino-
transferase (ABAT) as a potential GERD susceptibility gene
affecting control of the LES.
Methods
Ethics statement
Written informed consent was obtained before enrolment. All
data and DNA/tissue samples were coded. Ethical approval was
obtained for all patient collections and human research from the
Women’s and Children’s Hospital (Adelaide) Research Ethics
Committee with reference numbers REC1262/11/2004 &
REC1340/6/2005.
The adult case control cohort was approved by the Swedish
regional ethics review board in Umea ˚ with reference number 321/
03, diary nr 03-285.
All procedures involving laboratory animals were approved by
the regional animal ethics review board in Gothenburg, Sweden
with reference number 366-2005.
Patient collections
Three groups of GERD patients have been used in this study.
The first is a cohort of subjects of all ages in whom there is a
convincing family history of GERD (referred to as ‘‘Families’’).
The second is a cohort of children with GERD without a strong
family history of GERD, along with their parents (referred to as
‘‘Trios’’). The third is a collection of adult individuals suffering
from GERD together with healthy control individuals (referred to
as ‘‘adult case control cohort’’).
Ethnicity
The family and trio cohorts were collected from the diverse
multi-ethnic Australian population [24]. The ‘‘ethnic strength’’
describes how much a specific ethnicity contributes to a specific
population. For the Australian population, it is as follows:
approximately 70% Anglo-Celtic, 18% European (including
0.28% Swedish and 0.13% Finnish), 6% Asian, 1.5% Aborigi-
nal/Torrens Strait Islander and 4.5% African, Jewish, Pacific and
Indigenous American collectively. The adult case control cohort
was collected from north-eastern Sweden. This population is a
mixture of largely three ethnic groups where the Finnish and
Swedish contributions are roughly equal with an approximately
10% Saami admixture [25].
Families
Enrolment of patients was carried out in the Gastroenterology
Unit at Women’s and Children’s Hospital (WCH, Adelaide,
Australia), from 2001 to 2005 by identifying children (age up to 18
years) diagnosed with GERD and displaying at least one of the
following criteria within the last five years: an abnormal finding
from endoscopic examination or 24 hours esophageal pH test or
having been subjected to a fundoplication. Probands were
identified by examination of WCH patient records and by
contacting the local GERD support association (FIRSA; Friends
of Infant Reflux Support Association). Parents of the proband
were contacted and the family was enrolled if a positive family
history of GERD could be shown. Disease status was assessed via
physician diagnosis based on results of previously performed
investigations. Patients with a medical condition known to
predispose to GERD were excluded.
Trios
The trio cohort consisted of pediatric patients diagnosed with
GERD between three months and 17 years of age without
conditions predisposing to GERD, and their corresponding
parents. The diagnosis of GERD was based on the following: a
pediatric gastroenterologist’s evaluation of symptoms to be
consistent with GERD, in addition to either pH probe determined
acid exposure consistent with GERD, endoscopic findings
consistent with GERD and/or a definite and significant
improvement in symptoms of GERD shortly after commencing
anti-reflux treatment. Previous anti-reflux surgery was also
considered as evidence of GERD. Patients were identified from
databases of endoscopy, pH probe and outpatient diagnoses from
the Gastroenterology Unit at WCH. All the probands that were
endoscopically evaluated also had a histological examination of
esophageal biopsies. Grading of esophageal injuries found at
endoscopic examinations was based on the Tytgat classification
system [26], the most appropriate endoscopic grading system for
pediatric GERD [27]. The classification of the histological
examinations of esophageal biopsies was based on Knuff & Leape
[28,29]. There is a poor correlation between endoscopic
evaluation and histological examinations in GERD diagnosis
[27]. We therefore used both methods as inclusion criteria;
individuals with positive findings from either endoscopy or
histology evaluation were included in the trio cohort.
Patients were excluded if they had been diagnosed with a
condition predisposing to GERD, such as severe (non-ambulant)
cerebral palsy, cystic fibrosis, major congenital abnormalities of
the gastrointestinal tract (e.g. esophageal atresia/tracheo-esopha-
geal fistula), and severe chronic lung disease (for example oral
steroid dependent asthmatics and bronchopulmonary dysplasia).
The total number of individuals meeting these criteria was 219.
The average age was 6 K years and these patients had an average
BMI of 18.2 kg/m
2. The cohort consisted of 65% males. The
probands meeting the inclusion criteria were endoscopically
classified into grade 0 through 5 with the frequencies 20%,
58%, 16%, 4%, 1%, and 1%, respectively. Correspondingly,
histopathological grading resulted in 22%, 44%, 30%, 3%, 1%,
and 1% of patients classified with grades 0 through 5, respectively.
Adult GERD case control cohort
The Kalixanda cohort is a collection of patients from northern
Sweden where epidemiological factors related to GERD have
been investigated [30,31]. A careful description of this cohort has
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brief, all individuals went through an endoscopic examination that
together with a written questionnaire was used to diagnose GERD
by professional gastroenterologists. Using the same criteria and the
same physicians, we extended this cohort with 100 additional
GERD patients from the same demographic area, resulting in the
adult case control cohort used in this study. The cohort consists of
256 adult GERD cases (39% males) and 485 healthy control
individuals (46% males). The median age was 56 and 54 years in
the case and control groups respectively.
Animals
Ten adult Labrador retrievers were used in the study. Cervical
esophagostomies [32] were made. After recovery from surgery the
dogs were accustomed to rest in a Pavlov stand. Before the
experiments, the dogs were fasted for approximately 16–18 h, but
with free access to water.
Techniques
DNA extraction. DNA was extracted from blood or buccal
swabs using Qiagen (Qiagen, Valencia, CA, USA) or GenomPhi
(Amersham Biosciences AB, Uppsala, Sweden) according to
manufacturer’s protocol. In cases where DNA amount was
limited, whole genomes were amplified by Molecular Staging
Inc (Denver, CO, USA) through their Repli-g service.
Genotyping. Microsatellite genotyping was performed in 419
DNA samples using ABI Prism Linkage Mapping set v2.5 HD5 for
DNA fragment analysis (Applied Biosystems, Foster City, CA,
USA). Additional microsatellites were amplified using public primer
sequences. The forward primer was ordered 59-fluorophore labeled
(Sigma-Genosys, Cambridge, United Kingdom) while the reverse
primer was optimized [33]. Size fractioning of DNA fragments was
done in ABI 3700 or 3730 DNA analyzers (Applied Biosystems).
Alleles were called using the Genotyper v3.0 software (Applied
Biosystems). The mean distance between adjacent markers was 4.32
centimorgan (SD 6 2.65, range 0–14.78). Single nucleotide
polymorphism (SNP) genotyping was performed using the
TaqMan assay (Applied Biosystems) and detection in ABI
7900HT (Applied Biosystems) according to manufacturers
recommendations, apart from reducing the total reaction volume
to 2.5 ml. All data were analyzed with Sequence Detection Systems
 software v2.1 (Applied Biosystems).
Sequencing. Sequencing was performed from both directions
using the Applied Biosystems 3700 or 3730 automated DNA
sequencers (Applied Biosystems Inc) according to the
manufacturer’s recommendation. Sequence analysis was done
using (Sequencher 4.6, Genecodes, Ann Arbor, MI, USA) and
compared to the public genomic sequence (Ensembl release 49).
Sequence differences were manually checked and remaining
inconsistencies were resequenced.
Measurement of TLESR. The method applied for the
studies have been described previously [34]. Briefly, the dogs
were intubated with a water-perfused Dentsleeve multilumen
assembly to record the gastric, LES and esophageal pressures. An
antimony pH electrode was placed 3 cm above the LES for
measurement of acid reflux episodes and a water-perfused catheter
was placed in the hypopharynx to measure swallows. TLESRs
were stimulated by gastric infusion of an acidified liquid nutrient
(30 ml/kg; 100 ml/min) followed by air insufflation (500 ml/min)
to maintain a gastric pressure of 1061 mmHg during the
experiment. The number of TLESRs was measured during a
45 min period starting from infusion of the liquid. TLESRs were
defined as a rapid decrease in LES pressure (.1 mmHg/s), to a
pressure ,2 mmHg above gastric pressure and a duration .1s ,
without any pharyngeal signal ,2 s before onset. Reflux episodes
were defined as a drop in pH.1 unit within 5 seconds with an
average pH of ,4 in the 15 seconds following nadir pH.
Vigabatrin (SabrilexH) was dissolved in sterile water and
administered intragastrically (100 mg/kg; 0.5 ml/kg) 2 h before
start of measurement or 2 h and 16 h (100 mg/kg at each
occasion) before start of measurement.
Statistics
Quality Control of familial genotype data. Mendelian
inconsistencies were detected using PedCheck (v.1.1) [35].
Markers with a large number of errors were either reanalyzed or
excluded. Individual erroneous genotypes were either rechecked
or discarded. Hardy-Weinberg testing was performed in Pedstats
(v.0.6.4) [36]. Finally, Merlin (v.0.10.2) [37] and, in the case of
family 146, SimWalk2 (v.2.91) [38–40] were used to find unlikely
genotypes. Although markers deviating from Hardy-Weinberg
equilibrium and unlikely genotypes were not automatically
discarded, care was taken to ensure that they did not influence
the linkage peaks.
Quality control of the trio cohort and the adult case
control cohort genotype data
Mendelian inconsistencies in trio genotypes were detected using
PedCheck (v.1.1). Hardy-Weinberg testing as well as calculation of
descriptive statistics was performed in both Pedstats (v.0.6.4) and
Haploview v.3.32 [41] for both the Trios and the adult case
control cohort. Hardy-Weinberg testing was used as a tool to find
SNPs to reanalyze rather than to discard SNPs from the
association analysis. However, it was made sure that positive
associations could not be explained by deviations from Hardy-
Weinberg equilibrium.
Linkage analysis
Genetic map positions used in the linkage analysis were obtained
from the Decode map [42]. Markers that did not have an assigned
position were extrapolated into the map based on physical distance
to the flanking markers. Family wise multipoint LOD score curves
were calculated for all autosomal chromosomes and the X
chromosome using Genehunter v.2.1 [43,44] and, in the case of
family 146, SimWalk2 (v.2.91), assuming a dominant mode of
inheritance. Single point LOD scores were calculated and compared
to the multipoint LOD scores for data consistency. Linkages are
reported according to established guidelines, that is, suggestive and
significant linkage corresponding to LOD scores above 1.9 and 3.3
respectively [45]. The core linked region is defined as the region
where the LOD score is larger than the maximum LOD score
subtracted with 1 LOD unit (id est 5.5-1=4.5). Sensitivity analysis
was performed by (i) varying the parameters in the dominant model,
(ii) assessing an additive mode of inheritance, and (iii) performing
nonparametric analysis. These analyses provided no further
information and the results were thus omitted.
Association analysis trios
Transmission disequilibrium test (TDT) analysis based on single
SNPs was performed in Genehunter (v.2.1) and Haploview
(v.3.32). p-values adjusted for multiple testing (padj) were assessed
by permutations between transmitted and untransmitted alleles
using Haploview (v.3.32). The significance levels were also checked
using the Bonferroni correction (nominal p x 66 SNPs) for
consistency and no changes in significant association was found.
Linkage disequilibrium calculations (D9) and plots were generated
from genotype data in the trio cohort using Haploview.
Association between the Gene ABAT and GERD
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Allelic case-control analysis based on single SNPs, comparing
the allelic distribution between cases and controls in a 262 table,
was performed in SAS (v.8.2) using Fisher’s exact test. Since none
of the SNPs reached nominal significance (nominal p-value below
0.05, see the Results section), no adjustment for multiple testing
was performed. The analysis was also repeated comparing
genotypes in a 362 table.
TLESR Calculations in Dogs
Each dog served as its own control. Changes in the number of
TLESRs were calculated with regard to the mean of five preceding
control experiments for each dog. Data is presented as mean6
SEM. Student’s paired t-test was used for statistical analysis. A p-
value ,0.05 was regarded as statistically significant.
Results
Linkage analysis
Thirty-six families displaying dominant inheritance of GERD
were used for whole genome microsatellite genotyping and
subsequent linkage analysis. The outcome of the family wise
linkage analysis was the identification of one region reaching the
threshold for significant linkage and four regions reaching the
threshold for suggestive linkage (Table 1). A linked region on
chromosome 2 common for a subset of the families has been
publishedpreviously [17].Mostof theidentified linked regions were
large in size due to the limited number of individuals of the families
used. However, two of the families displayed an overlapping linkage
to a relatively small region located on chromosome 16p.
Furthermore, the linkage for one of these families was significant,
reaching a maximum LOD of 3.9. The other family displayed a
completely overlapping linkage curve and reached a suggestive
linkage of 2.0 (Figure 1). Additional microsatellite genotyping
reduced the extent of the region. Hypothesizing that the same
genetic perturbation was causative in these two families, we reached
a combined LOD score of 5.5 (Figure 1). The size of the region, as
defined by the closest unlinked markers, common to both families,
was 5.1 mega base pairs (Mbp). While the core linked region
spanned only 3.6 Mbp, we were not able to reduce the linkage
region any further through linkage analysis due to absence of
recombination events in the core linked region.
Genetic association analysis of the trio cohort
The identified chromosomal region defined by the combined
linkage curves was relatively small and contained 9 genes
(Figure 2). We argued that the causative gene most likely would
be a common GERD gene, present in other GERD patients. To
test this we decided to investigate if any of the genes located in the
linked region were genetically associated with GERD in an
independent pediatric GERD trio cohort. We selected and
genotyped 66 different SNP markers located in, and around, the
9 genes. Transmission disequilibrium test analysis, followed by
multiple testing adjustments for all 66 SNPs genotyped, revealed
significant genetic association for the SNP rs1641021. This SNP
reaches an adjusted p-value of 0.027 (calculated as the nominal p-
value 0.0004 multiplied with 66). The data for this SNP, together
with the 16 other SNPs located in the ABAT region, are shown in
table 2. The associated SNP, rs1641021, is located within intron
16 of ABAT.
The genetic association we identified for rs1641021 could
originate from ABAT, or depending on the Linkage Disequilib-
rium (LD) properties of the region, from a gene located nearby.
We therefore constructed a LD map from the trios used in this
study (Figure 3). This map shows that rs1641021 lies outside an
LD block which covers the 39 end of ABAT together with the
neighboring genes TMEM186, PMM2 and CARHSP1. The LD
structure, surrounding the associated SNP rs1641021, implies that
this marker is linked with a nearby located true disease associated
mutation. We therefore conclude that the association seen for
rs1641021 originates from ABAT.
Genetic association analysis of the adult case control
cohort
In an effort to replicate the association in the trio cohort, nine
SNPs distributed over the ABAT LD block were genotyped in the
adult case control cohort (Table 2). The associated SNP in the trio
cohort (rs1641021) reached a nominal p=0.34 (nominal p value
between 0.24 and 0.94 for the other SNPs). None of the genotyped
SNPs showed an indication for association. The allele frequency of
rs1641021 did not differ between the trio cohort (41%), the
controls in the case-control cohort (45%) or the frequency
published for Caucasians in the Hapmap project (42.4%) [46].
The statistical power was calculated in this cohort by estimating
the risk ratio in trios for the minor versus major allele to 1.67 (122/
73). Assuming a minor allele frequency of 0.4 in controls, a risk
ratio of 1.5, and that 250 cases and 475 controls have been
successfully genotyped, the power to replicate the rs1641021
association in the adult case-control cohort was 95%. The power
was 80% to detect an association at the level of significance 0.0055
(Bonferroni correction for 9 SNPs).
Table 1. A summary of the five linked regions identified in the GERD family collection.
Families displaying genetic linkage to GERD
Family
Number of
individuals
GERD
individuals
Unassigned
individuals
Linked
Chromosome LOD Score Linked region Outer markers
101 30(14) 11(3) 7(5) 5 2.3 D5S1982-D5S424 D5S647 D5S672
103 14(8) 11(7) 0(0) 6 2.5 D6S291-D6S1570 D6S276 D6S300
122 20(10) 10(7) 5(1) 16 2.0 D16S506-D16S407 D16S423 D16S3122
146 34(14) 16(6) 6(3) 16 3.9 D16S506-D16S407 D16S423 D16S3122
103 14(8) 11(7) 0(0) 18 2.5 D18S1132-D18S1163 D18S1372 D18S464
The table shows that suggestive linkage was found on chromosome 5, 6, 16 and 18. Significant linkage was found on chromosome 16. Number of GERD individuals and
individuals with unassigned disease status are presented for each family (number of males in parenthesis). The remaining individuals are healthy. The linked region is
defined as the utmost markers included in the genetic linkage log of Odds (LOD) score peak while outer markers are defined as the closest genotyped unlinked marker.
doi:10.1371/journal.pone.0019095.t001
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We subsequently sequenced the entire coding sequence of
ABAT, including intron-exon splicing boundaries, in three
affected and three healthy individuals from each of the two
families showing linkage to chromosome 16p. No amino acid
changing mutation was identified.
TLESR measurements in dogs
In an attempt to better understand the role of ABAT in
GERD, we assessed the effect of vigabatrin, a selective
irreversible inhibitor of ABAT, on TLESRs in dogs. A single
dose of vigabatrin, administered 2 h (100 mg/kg) before the start
of the experiments, produced a statistically significant inhibition
of TLESRs by 30%69.8%. When vigabatrin (100 mg/kg) was
administered twice (at 2 h and 16 h) before the experiment, the
inhibitory effect was further increased to 57.3%611.4%
(Figure 4A). The average number of TLESRs in all control
experiments was 9.960.5. In addition, vigabatrin produced a
statistically significant reduction of the number of acid reflux
episodes from 3.160.4 (control) to 0.860.4 (100 mg/kg dosed
2 h and 16 h) during the 45 min measurement period. A single
dose of vigabatrin produced no significant reduction of reflux
episodes (360.4 and 260.5 in control and vigabatrin treated
animals, respectively) (Figure 4B).
Figure 1. Overlapping linkage peak at chromosome 16p for families 122 and 146. Strongest linkage was obtained for family 146 showing a
LOD of 3.9. The other family, 122, showed a linkage of LOD 2.0. The combined linkage curve reaches a maximal LOD score of 5.5.
doi:10.1371/journal.pone.0019095.g001
Figure 2. The linked region at chromosome 16p. The box represents the region of the combined maximum LOD-1. This approximates a 95%
confidence interval for the location of the linked candidate gene and covers approximately 5 Mbp. The genes located within the region are; Ataxin
Binding Protein 1 (A2BP1), chromosome 16 open reading frame 68 (C16ORF68), 4-aminobutyrate aminotransferase (ABAT), transmembrane protein
186 (TMEM186), phosphomannomutase 2 (PMM2), calcium regulated heat stable protein 1, 24 kDa (CARHSP1), ubiquitin specific peptidase 7 (USP7),
chromosome 16 open reading frame 72 (C16ORF72) and glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A).
doi:10.1371/journal.pone.0019095.g002
Association between the Gene ABAT and GERD
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19095Discussion
We have investigated the genetic predisposition to GERD using
three different patient cohorts. We started by performing a linkage
analysis in a collection of 36 families with the aim to identify both
general and family specific linked chromosomal regions. These
families were selected for the presence of GERD in every
generation, in a dominant fashion, to maximize the genetic signal.
We analyzed the linkage data both collectively (as previously
published in [17]) and familywise and it became clear to us from
this analysis, where we demonstrate linkage to five different
chromosomal regions, that GERD is a disease with many different
genetic predispositions.
In the remainder of this work we focused on the two families
that showed linkage to the same region on chromosome 16. These
linkages were identical to the resolution provided by microsatellite
mapping and although the region was relatively small, it contained
nine genes.
To investigate if any of these nine genes were genetically
associated with GERD we used a separate patient collection with
sufficient resolution to allow mapping of single genes. We
genotyped 66 SNPs distributed over the nine genes in a pediatric
GERD trio cohort. Applying multiple testing adjustments using
permutations analysis we identified a significant association in
ABAT, but not in any of the other genes, showing that ABAT is a
GERD associated gene in our pediatric GERD population. The
cohort consists of more males than females but we cannot detect a
gender bias in the association. We attempted to replicate the
genetic association in ABAT using an adult Swedish GERD case-
control cohort by testing the associated ABAT SNP together with
surrounding SNPs but found no evidence for genetic association.
Statistical power estimates do not explain the lack of replication in
this cohort.
This absence of association may be due to the fact that the
proband in the Australian families were pediatric cases, the trio
cohort is also pediatric and collected in Australia but the Swedish
case-control cohort consists of adult GERD cases. Furthermore,
the population history clearly differs between the two cohorts. The
adult case-control cohort is a mixed Swedish and Finnish material
with Saami influence while the trio cohort is mainly Anglo-Celtic.
In our previous publication, we demonstrated that COL3A1
alleles were reciprocally associated with GERD (see table 2 in [17])
implicating that GERD mutations have arisen separately in these
two different patient cohorts. Our conclusion is that ABAT alleles
are not present as genetic risk factors for GERD in the Swedish
adult case control cohort. However, the statistically significant
association in the trio cohort clearly shows that one polymorphic
variant within ABAT is associated to GERD. From our
sequencing results we demonstrate that the open reading frame
of the ABAT gene is intact. The few known disease causing
mutations in the ABAT protein cause psychomotor retardation
and early death [47,48]. Perhaps severe mutations are not to be
expected in a disease such as GERD. More likely, a GERD
associated mutation in ABAT may be expected to be located in
non-coding sequences such as regulatory elements or non coding
RNAs, as has recently been discussed in the literature regarding
complex diseases [49].
Due to ABATs predominant expression in neuronal tissues it
was not possible to investigate the function of ABAT in GERD
patients because suitable samples were unobtainable to us. Instead,
Table 2. Genetic association in the trio cohort.
Transmission disequilibrium test analysis for the genotyped SNPs located in the ABAT gene region of chromosome 16
All Individuals n=219 Endoscopy positive n=177 Histology positive n=175
# SNP T:U p-val padj T:U p-val padj T:U p-val padj
3 rs2302607 61:61 1 1 55:49 0.56 1 49:48 0.92 1
4 rs1273350 90:65 0.045 0.91 71:50 0.056 0.96 77:50 0.017 0.60
5 rs6497327 97:81 0.23 1 79:67 0.32 1 81:68 0.29 1
6 rs1940989 89:83 0.65 1 76:67 0.45 1 70:66 0.73 1
7 rs1731017 88:85 0.82 1 74:71 0.80 1 68:68 1 1
8 rs1273398 29:26 0.69 1 22:21 0.88 1 25:22 0.66 1
9 rs1641021* 122:73 0.0004 0.027 100:57 0.0006 0.037 100:54 0.0002 0.012
10 rs1079348* 112:86 0.065 0.97 96:67 0.023 0.72 90:67 0.066 0.97
11 rs3743798* 112:102 0.49 1 96:85 0.41 1 88:79 0.49 1
12 rs2304471* 80:60 0.091 0.99 68:48 0.063 0.97 64:44 0.054 0.94
13 rs67497537* 100:71 0.027 0.77 89:57 0.0081 0.37 81:51 0.0090 0.39
14 rs28595449* 83:56 0.022 0.69 72:45 0.013 0.51 69:40 0.0055 0.26
15 rs2075827* 90:62 0.023 0.72 77:50 0.017 0.62 74:45 0.0079 0.35
16 rs1657070* 99:87 0.38 1 84:68 0.19 1 79:69 0.41 1
17 rs8097 98:98 1 1 83:81 0.88 1 80:80 1 1
18 rs2304446 72:60 0.30 1 57:50 0.50 1 58:48 0.38 1
19 rs30764 73:71 0.87 1 62:53 0.40 1 61:59 0.86 1
A total of 66 SNPs were genotyped in the linked region on chromosome 16 and subsequently analyzed with TDT. The table shows a subset of these located around
ABAT. T:U denotes the number of transmitted versus untransmitted alleles. p-val is the nominal p value. padj is the p-value adjusted for multiple testing through
permutation analysis for the full 66 SNP panel. The trio cohort consists of 177 probands with positive findings from endoscopy evaluation and 175 probands with
positive findings from histology evaluation. In total the cohort consist of 219 trios. The eight SNPs marked with an asterisk were also genotyped in the adult case control
cohort in addition to rs8046201.
doi:10.1371/journal.pone.0019095.t002
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19095Figure 3. LD map of the region containing ABAT. The associated SNP, rs1641021 is located adjacent to a LD block covering the 39 part of ABAT
together with TMEM186, PMM2 and CARHSP1.
doi:10.1371/journal.pone.0019095.g003
Figure 4. Analysis of ABAT inhibition in dogs. Inhibition of TLESRs (A) and reflux episodes (B) in dogs after administration of the ABAT specific
inhibitor Vigabatrin. Administration was performed 2 hours or 2 and 16 hours before measurements. Each group consisted of six dogs. TLESR and
reflux events are presented as number of events/45 minutes. P-values were calculated using paired t-test. Open boxes represent the control
experiment, filled boxes are after the administration of Vigabatrin, n.s. denotes not significant.
doi:10.1371/journal.pone.0019095.g004
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19095we investigated how ABAT perturbation may lead to the
development of GERD through inhibition of ABAT function in
vivo in dogs. Administration of the ABAT specific inhibitor
vigabatrin significantly inhibited TLESRs and reflux episodes in
dogs. This result implies that humans carrying disease associated
ABAT alleles may suffer from an increased number of reflux
episodes due to dysregulation of the LES.
ABAT catalyses the first step in the degradation of GABA.
Inhibition of ABAT leads to elevated levels of GABA in the
synaptic junctions causing increased GABA-mediated signaling
through the GABA receptors [50]. The neurotransmitter GABA is
involved in the control of the LES [51]. Signaling through both
GABAA [52] and especially GABAB receptors reduces TLESRs, as
shown with GABAB receptor agonists [53]. TLESRs are the major
motility factor underlying GERD [54] and these relaxations result
in an increased frequency of reflux episodes [55] thereby causing
esophageal mucosal damage.
The previously published association between COL3A1 and
GERD [17] represents a disease mechanism presumably involving
tissue vulnerability of the esophagus. The ABAT association we
present here indicates that GERD in addition has a neuronal
disease component.
Our results leading to the identification of ABAT are in line
with the ongoing efforts to develop antireflux drugs to treat
GERD. These drugs are GABA analogs specifically directed
against the GABAB receptor [53]. Our findings support the
involvement of GABA with GERD. This raises the question of
whether other GABA signaling components such as transporters
and receptors are associated with GERD as well.
In conclusion, we show that a polymorphic variant within the
ABAT gene is associated with GERD and that ABAT inhibition
leads to a reduction of TLESRs and acid reflux events. Our results
raise the possibility of treating GERD by inhibiting ABAT
function.
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